Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Pre-order your Brochure
Reserve your place

2017's Speaker Line-up

Kate Knobil

Kate Knobil

Chief Medical Officer, Pharmaceuticals, GSK

Read more

Kate is the Chief Medical Officer for Pharmaceuticals at GSK. The mission of her group (Pharma Medical and Patient Safety) is to understand the current and future needs of patients, clinicians and healthcare systems to generate and communicate evidence that informs on the benefits, risks and overall value of GSK medicines.

Kirk Shepard

Kirk Shepard

President, Medical Affairs Professional Society & Senior Vice President, Head of Global Medical Affairs Oncology, Eisai Pharma

Read more

Dr. Kirk Shepard is the 2016-2017 President of the Medical Affairs Professional Society (MAPS) and has more than 25 years of experience in the pharmaceutical industry. He is a board-certified medical oncologist and hematologist physician. He is currently Senior Vice President, Head of Global Medical Affairs Oncology at Eisai Pharmaceutical Company.

Dr. Shepard’s experience in multiple therapeutic areas includes operational and strategic product development from Phases I through IV and the diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, health economics & outcomes research & patient access, data generation, field-based medical teams (MSLs), PV/safety, medical communication & publications, patient advocacy, and public relations. In 2015, he was selected as one of the 100 Most Inspiring People in the Pharmaceutical Industry (PharmaVOICE).  Before his pharmaceutical career, Dr. Shepard served as a staff physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic Foundation, where he supervised numerous studies in oncology and symptom control. He has more than 50 medical publications in journals and books.

Dr. Shepard earned his bachelor’s degree from Cornell University in Ithaca, NY, and his medical degree from the University of Cincinnati Medical School in Cincinnati, OH. He completed both his internship and residency in internal medicine at Case Western Reserve University in Cleveland, OH, and fellowships in hematology and oncology at the University of Chicago Hospitals and Clinics in Chicago, IL.

Alan Wright

Alan Wright

Chief Medical Officer, Roche Diagnostics

Read more

As the Chief Medical Officer for Roche Diagnostics Corporation, Alan serves as our clinical spokesperson and lead counsel on everything from the policy to the practice of diagnostic medicine. With his extensive history in the managed care, pharmaceutical and biotechnology industries, Alan is well-versed in the changing landscape of healthcare including emerging trends and technologies, regulatory and legislative hurdles, payer challenges and the growing relevance of diagnostics with the advent of outcome-based reimbursement.

Alan brings with him medical and scientific leadership experience from his work from a variet. He earned his medical degree from University of Pennsylvania School of Medicine and a masters of public health degree from Johns Hopkins School of Public Health and Hygiene.

Shontelle Dodson

Shontelle Dodson

Vice President, Medical Excellence/Medical Affairs Global, Astellas

Read more

Dr. Shontelle Dodson is Vice President, Medical Excellence within the Global Medical Affairs organization at Astellas Pharma and has extensive clinical and research experience in the healthcare and pharmaceutical industries. After several years of service in direct patient care at the Department of Veterans Affairs, Shontelle spent 11 years at Pfizer, Inc. in various Medical Affairs leadership roles across the Urology and Respiratory franchises. Following her work with Pfizer, she served as Vice President, Medical Affairs at GTx, Inc. In this capacity Shontelle led the Phase 3 clinical development of a selective androgen receptor modulator for the prevention and treatment of muscle wasting in patients with cancer including incorporating key economic and health outcomes assessments to support product utilization and valuation. Under her leadership at Astellas, the Medical Affairs group has pioneered multiple, innovative real world data projects including two national registries in prostate cancer and overactive bladder, as well as partnered research with leading managed care and academic organizations.

Shontelle has received multiple awards for leadership and innovation during her career, including the National Healthcare Business Women’s Association Rising Star and Astellas Vision Award. Dr. Dodson holds a Doctor of Pharmacy degree from Mercer University School of Pharmacy and completed a postdoctoral residency at the Department of Veterans Affairs Medical Center in Nashville, Tennessee.

Rosh Dias

Rosh Dias

Vice President, Global Scientific Affairs, Amgen

Read more

Rosh Dias, M.D., MRCP, is a UK trained physician with 17 year’s industry experience in a set of functionally and geographically diverse Medical Affairs roles in both large pharma and biotech.

Currently serving as Vice President of Global Scientific Affairs at Amgen, he leads global and regional organizations responsible for Scientific Communications, Medical Writing, and Medical Science Liaisons across all Amgen therapeutic areas.

Rosh has had prior roles at Onyx Pharmaceuticals, and Novartis Oncology, where he has led Global Medical Affairs programs for key compounds, Country Medical Organizations, and Field Medical Organizations.

Paul Rowe

Paul Rowe

Vice President, Global Medical Affairs Head, Airway/Respiratory, Sanofi Genzyme

Read more

Dr. Rowe has well over a decade of research experience spanning from pre-clinical to late phase drug development programs, primarily in respiratory (and cardiovascular) medicine. He has been directly responsible for medical strategy and lifecycle management of several Chronic Obstructive Pulmonary Disease (COPD), asthma, and cardiovascular medicines. Dr. Rowe has been successfully involved in achieving New Drug Application (NDA) approvals for first in therapeutic class respiratory products and also has led various clinical development global projects from phase II through phase IV clinical trials. He has authored and co-authored several publications in respiratory medicine (COPD-focused, and is a frequent lecturer and speaker at professional society meetings, and educational forums. Dr. Rowe holds degrees from Harvard University and the University of Rochester School of Medicine, and certifications from the London School of Economics and Villanova University.

Dr. Rowe is an active member of several national and international societies and he recently served as Vice Chair of the Drug, Device, Discovery, and Development Committee of the American Thoracic Society (ATS). He has a primary interest in promoting international medical research collaboration and innovation across government, academia, and industry.

In his current role, Dr. Rowe is responsible for building and leading a Global Medical Affairs team and strategy within the respiratory space for several novel compounds in mid and late stage development, in various therapeutic indications.

Stanislav Glezer

Stanislav Glezer

former Vice President, Medical Affairs, Novo Nordisk

Read more

Stan Glezer, MD, MBA is an industry physician, passionate in optimizing value of phamecutical innovation for the patients, through partnering with the healthcare system.

Until recently, he served as Vice President of US Medical Affairs at Novo Nordisk Inc. Prior to joining Novo Nordisk, Stan has worked at Sanofi where, most recently, he led the development, regulatory submission, and launch preparation of Toujeo.

He brings with him extensive knowledge of medical affairs at an affiliate and Global level, as well as of the commercial areas of pharmacueitcal business and has held leadership roles in post-marketing research, epidemiology, medical information, medical communications, HEOR, interfacing with regulatory agencies, market access, and overall lifecycle management

Although his activities in the past few years were predominatly focused on diabetes, Stan has worked in multiple theraputic areas, including osteoporosis, oncology, immuno-inflammation, obesity, thrombosis, bleeding disorder and rare diseases. HE has a strong track record of leading the teams in establishing collaborations with healthcare providers, key opinion leaders, payers, and professional associations.

Stan received his medical training in Russia and has worked in Canada and in France for the past 20 years. He has an MBA from California Coast University and completed his graduate work in Clinical Research at McGill University.

Dana Evans

Dana Evans

Director for Patient Access, Collaboration and Exchange, Genentech

Read more

Dana Evans is the Director for Patient Access, Collaboration and Exchange with Genentech Medical Affairs. Dr. Evans manages a team of clinicians that provides scientific, clinical and managed care professional support to account teams who are responsible for payers, hospitals, government programs, group purchasing organizations and product distribution companies.

Dr. Evans obtained his medical degree from the University of Texas Medical School at Houston and completed his residency in Family Medicine at Southwest Memorial Hospital in Houston. He practiced family medicine in Texas, including obstetrics and surgery, for seven years. In 1992, he left clinical practice to begin a career in administrative medicine. His resume includes positions as medical director, chief medical officer and executive officer for regional and national health plans. He has also been a managed care consultant for health plans and physician organizations. He moved to the pharmaceutical industry as a medical director for managed care with GlaxoSmithKline in 2001. Dr. Evans joined Genentech in 2008 as a medical director for Value Based Healthcare.

Lav (Bobby) Parvathenani

Lav (Bobby) Parvathenani

Specialty Medical Information Lead, US Medical, Bristol-Myers Squibb

Read more

More information coming soon...

Diane McDowell

Diane McDowell

Head, Global Scientific Affairs Oncology, GSK

Read more

Diane McDowell recently returned to GlaxoSmithKline with over ten years of industry experience. Diane is a fellowship trained, board certified, surgical oncologist. She is also an award winning, pharmaceutical executive with oncology and immuno-oncology experience in both clinical development and medical affairs. Diane’s work has spanned both US and international markets for Bristol-Myers Squibb, GlaxoSmithKline, and Merck. Diane’s clinical development experience includes indication file lead and regulatory interaction. Her Medical Affairs experience includes building and leading large teams, medical matrix team creation and management, Phase IV study leadership and Investigator Sponsored Study Program leadership.

Prior to joining industry Diane was in clinical practice as a general and breast cancer surgeon. Diane completed her fellowship training at Fox Chase Cancer Center, and her surgery residency at Tulane University and Charity Hospital in New Orleans. Her industry career started at BMS in 2007 where she spent over 5 years in various roles. Starting as US medical lead for Ixempra in breast cancer, and expanding into other roles including a regional role in the EU launch of Yervoy in melanoma, Medical Affairs lead for the Imclone/BMS lung cancer initiatives involving Necitumumab, and medical monitor for both lung and melanoma ipilimumab trials. In her capacity on the Yervoy team, she was involved in the Yervoy safety management training and education of her peers as well as external investigators.

In 2013, she joined GSK as an Executive Director, Medical Affairs Lead for Tafinlar/Mekinist where she created and implemented a plan for successful launch of Tafinlar/Mekinist into the U.S. Market. She led cross functional collaboration to develop and execute the USMA plan for combination therapy, led Phase IV studies, and served as medical point person for external communication and advocacy groups. In 2015, Diane was asked to lead US Oncology Global Medical Affairs at Merck. While there, Diane built a team of over forty-five people to support the growing Keytruda franchise.

Roslyn Schneider

Roslyn Schneider

Global Patient Affairs Lead, Pfizer

Read more

Roz is the Global Patient Affairs (GPA) Lead within Pfizer’s Chief Medical Office. Roz’s team drives more systematic, end to end patient centricity at Pfizer. She received her BS from the Sophie Davis School of Biomedical Education of the City College of New York, MD from Mount Sinai School of Medicine, and MSc in Pharmaceutical Medicine from Hibernia College. A retired Clinical Professor of Medicine of Albert Einstein College of Medicine, an Internist, Pulmonologist, Intensivist, she practiced for twenty years. She published in the areas of pulmonary complications of HIV infection, venous thromboembolic disease, medical ethics and medical education.

Karen Lowney

Karen Lowney

Executive Director, Global Compliance, Privacy & Transparency, Astellas

Read more

Karen Lowney is the Executive Director, Global Compliance, Privacy & Transparency at Astellas Pharma, where she is responsible for providing compliance support to Global functions, including Development, Medical Affairs and Marketing Strategy. She is responsible for Transparency Reporting as well as managing systems and processes that govern various interactions with healthcare professionals and healthcare organizations. She also serves as the Americas Privacy Officer.

Prior to Astellas, Karen was the Senior Director of Global Compliance at Cephalon, where she managed compliance across business units including the development, implementation and oversight of policies, procedures and processes, employee training, aggregate spend tracking and government reporting, monitoring, incident management and investigations, and providing day-to-day advice to business partners.

Karen previously served as the Director of International Compliance at Schering-Plough where she was responsible for implementation of compliance initiatives within the Global Pharmaceutical Business, coordination of their compliance officer network, and ensuring policies, procedures and processes adhered to corporate guidelines as well as local laws, codes and regulations.

She holds a B.S.B.A in Accounting from the University of Missouri and is a Certified Internal Auditor.

Leonard Friedland

Leonard Friedland

Vice President, Director Scientific Affairs and Public Policy, Vaccines North America, GSK

Read more

Dr. Leonard Friedland is Vice President, Director Scientific Affairs and Public Health, Vaccines North America at GSK. He is also a licensed pediatrician in the state of Pennsylvania. Dr. Friedland has held many positions in clinical research and development with GSK since 2003, specializing in infectious disease vaccination.

Prior to his work at GSK, Dr. Friedland was Division Chief, Pediatric Emergency Medicine at Temple University School of Medicine. Dr. Friedland studied medicine at Mount Sinai School of Medicine in New York and conducted his residency in pediatrics at the Children's Hospital of Philadelphia and his fellowship in pediatric emergency medicine at St. Christopher's Hospital for Children, also in Philadelphia.

He is currently a fellow and active member of the American Academy of Pediatrics and has published over 39 peer reviewed articles during his career.

Janet Baldwin

Janet Baldwin

Vice President, Real World and Late Phase, INC Research

Read more

Janet Baldwin has over 30 years of drug development experience, working for both large pharma and clinical research organizations. She has a B.S. in Biochemistry and began her career as an analytical chemist developing and validating methods for detection of new drug entities in the pre-clinical and clinical pharmacology settings. Her responsibilities included the development of an analytical lab in support of the bioanalytical group at Hoffmann – La Roche. Janet then became a Clinical Research Associate where she developed protocols, CRFs and recruited and managed sites for multiple phase II and III studies. Her career progressed to clinical study/trial management and then department management. Janet has built and lead departments across a number of functional areas including, project management, analytics, clinical research, feasibility, site identification and patient recruitment. For the past 10 years Janet has focused on Late Phase Research. While at Quintiles, Janet was the Americas Head of Late Phase Project Management and Analytics, designing and overseeing Observational (both prospective and retrospective), phase IV interventional, large Outcomes Studies and Expanded Access Programs (EAPs). Her experience also includes serving as a principal investigator for an observational study where patients were recruited using pharmacy data. As Global Head of Clinical Operations, Observational Research at PAREXEL, she created a clinical team for the purpose of providing site management support for observational studies. Janet is currently Vice President for Real World and Late Phase at INC Research.

Elizabeth Engelhardt

Elizabeth Engelhardt

Head of Specialty Strategy & Clinical Management, Aetna

Read more

Elizabeth Engelhardt is the Head of Specialty Strategy and Clinical Management Programs for Aetna Pharmacy Management. In this role Ms. Engelhardt is accountable for the development, design and execution of clinically sound, cost conscious Specialty medical and pharmacy pharmaceutical management for Aetna Commercial members. Prior to her current role, Ms. Engelhardt was the Director of Trade Relations for Aetna Pharmacy Management, accountable for setting strategic plans for Aetna’s relationships with Pharmaceutical Manufacturers, managing a portfolio of rebate contracts and creating and maintaining valuable partnerships within the manufacturer community. She joined Aetna in 2011.

In addition to her Aetna experience, Ms. Engelhardt held management positions within the health care industry with various companies including Novartis Oncology, BioScrip, Inc, Teva Pharmaceuticals and Merck. Her clinical experience includes Pediatric Nursing, Pediatric Oncology Nursing, Adult Oncology Nursing and Nurse Management.

She holds a Bachelor of Science degree in Nursing from Molloy College, Rockville Center, NY.

Soumi Saha

Soumi Saha

Assistant Director of Pharmacy & Regulatory Affairs, Academy of Managed Care Pharmacy (AMCP)

Read more

Soumi Saha serves as the Assistant Director of Pharmacy & Regulatory Affairs at the Academy of Managed Care Pharmacy (AMCP). Soumi joined AMCP in July 2015 and is responsible for advancing the interests of its members by advocating the Academy’s regulatory positions at the federal and state level. Prior to joining AMCP, Soumi worked for Kaiser Permanente where she held various positions and most recently served as the Director of National Pharmacy Controls. Soumi has a Doctor of Pharmacy (PharmD) from the University of Maryland School of Pharmacy and a Juris Doctor (JD) with a concentration in Health Law from the University of Maryland School of Law.

Patrick Reilly

Patrick Reilly

CEO, phactMI

Read more

Patrick Reilly is currently CEO for phactMITM, a collaboration of pharmaceutical company Medical Information (MI) departments that are dedicated to supporting healthcare professionals in their commitment to provide quality patient care. Patrick is also principal at Reilly Consulting, LLC, focusing on pharmaceutical medical affairs management.

Patrick has spent the past 30 years within the Pharmaceutical Industry, primarily at Bristol Myers Squibb within the R&D/Medical Affairs organization. During his tenure at BMS, Patrick worked in a variety of leadership roles with a focus on building and enhancing organizational capabilities like clinical trial monitoring, global field medical, and most recently globalizing medical information.

As Vice President of Medical Information at BMS he led the globalization of the organization, leveraging technology and establishing innovative multi-channels to enhance the exchange of medical and scientific information for HCPs. Patrick was also actively involved in the people strategy at BMS, talent acquisition and development, where he was the executive sponsor of the PharmD Fellowship/Residency program.

Patrick has a bachelor’s degree in Biology, a bachelor’s degree in Medical Science (as a Physician Assistant) and a Master’s Degree in Business administration. He is an active member of the Drug Information Association (DIA) and the American Society of Association Executives (ASAE) and is a frequent presenter at Life Sciences conferences.

Lynn Vos

Lynn Vos

CEO, ghg | greyhealth group

Read more

More information coming soon...

Joe Kohles

Joe Kohles

Chief Medical Officer, Envision Pharma Group

Read more

More information coming soon...

Honorio Silva

Honorio Silva

President, IFAPP (International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine)

Read more

Dr. Silva’s professional career has focused on fostering clinical research and medical education with focus on emerging countries, in addition to serving the pharmaceutical industry, academia and various professional associations. After 30-years of service with Pfizer Inc, Dr. Silva retired as Vice President, Science and Medical Professional Development, within the External Medical Affairs group. He also served as Vice President, Medical and Regulatory Affairs, Japan, Asia, Africa & Latin America and Director/Team Leader Medical Operations, Latin America & Canada. He was also Assistant Professor of Clinical Pharmacology at the Universidad Central de Venezuela Medical School.

Pre-order the detailed event brochure

Get the agenda and speaker line-up to your inbox – Pre-order the brochure